| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Denosumab in postmenopausal women with low bone mineral density.
|
N Engl J Med
|
2006
|
10.02
|
|
2
|
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
|
Arch Intern Med
|
2004
|
3.93
|
|
3
|
Osteoporosis and fracture risk in women of different ethnic groups.
|
J Bone Miner Res
|
2004
|
3.37
|
|
4
|
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
|
Endocr Rev
|
2005
|
3.01
|
|
5
|
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
|
J Bone Miner Res
|
2007
|
2.68
|
|
6
|
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
|
Arch Intern Med
|
2005
|
2.60
|
|
7
|
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
|
J Bone Miner Res
|
2011
|
2.53
|
|
8
|
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
|
Kidney Int
|
2008
|
2.29
|
|
9
|
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.
|
J Bone Miner Res
|
2009
|
2.24
|
|
10
|
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
|
J Clin Endocrinol Metab
|
2002
|
2.16
|
|
11
|
The 2002 Canadian bone densitometry recommendations: take-home messages.
|
CMAJ
|
2002
|
1.92
|
|
12
|
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
|
Am J Med
|
2012
|
1.80
|
|
13
|
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
|
Curr Med Res Opin
|
2008
|
1.79
|
|
14
|
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
|
J Bone Miner Res
|
2004
|
1.76
|
|
15
|
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.
|
J Clin Densitom
|
2008
|
1.76
|
|
16
|
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.
|
J Bone Miner Res
|
2010
|
1.74
|
|
17
|
Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment.
|
Obstet Gynecol
|
2004
|
1.68
|
|
18
|
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions.
|
J Clin Densitom
|
2008
|
1.66
|
|
19
|
White-rot fungi demonstrate first biodegradation of phenolic resin.
|
Environ Sci Technol
|
2006
|
1.64
|
|
20
|
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
|
J Clin Endocrinol Metab
|
2011
|
1.59
|
|
21
|
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
|
J Bone Miner Res
|
2006
|
1.58
|
|
22
|
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
|
J Bone Miner Res
|
2010
|
1.54
|
|
23
|
Effects of denosumab on fracture and bone mineral density by level of kidney function.
|
J Bone Miner Res
|
2011
|
1.40
|
|
24
|
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
|
J Clin Endocrinol Metab
|
2012
|
1.38
|
|
25
|
Benefits and risks of bisphosphonate therapy for osteoporosis.
|
J Clin Endocrinol Metab
|
2012
|
1.24
|
|
26
|
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
|
Contraception
|
2006
|
1.21
|
|
27
|
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children.
|
J Clin Densitom
|
2004
|
1.18
|
|
28
|
Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.
|
Clin Ther
|
2004
|
1.17
|
|
29
|
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
|
J Bone Miner Res
|
2011
|
1.14
|
|
30
|
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
|
Ann Intern Med
|
2002
|
1.12
|
|
31
|
Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
|
J Bone Miner Res
|
2007
|
1.12
|
|
32
|
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.
|
J Clin Endocrinol Metab
|
2012
|
1.09
|
|
33
|
Secondary and tertiary hyperparathyroidism.
|
J Clin Densitom
|
2012
|
1.07
|
|
34
|
It's hard to be a real doctor now.
|
Pharos Alpha Omega Alpha Honor Med Soc
|
2015
|
1.07
|
|
35
|
Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions.
|
J Clin Densitom
|
2006
|
1.04
|
|
36
|
Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
|
J Bone Miner Res
|
2009
|
1.04
|
|
37
|
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.
|
J Bone Miner Res
|
2012
|
1.03
|
|
38
|
Safety of bisphosphonates in the treatment of osteoporosis.
|
Am J Med
|
2009
|
1.02
|
|
39
|
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence.
|
J Bone Miner Res
|
2004
|
1.00
|
|
40
|
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
|
Curr Med Res Opin
|
2005
|
0.98
|
|
41
|
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis.
|
Ther Adv Musculoskelet Dis
|
2011
|
0.96
|
|
42
|
Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001.
|
J Clin Densitom
|
2002
|
0.95
|
|
43
|
Bone and kidney disease: diagnostic and therapeutic implications.
|
Curr Rheumatol Rep
|
2012
|
0.95
|
|
44
|
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
|
Anticancer Res
|
2009
|
0.94
|
|
45
|
Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension.
|
J Bone Miner Res
|
2014
|
0.91
|
|
46
|
More bone density testing is needed, not less.
|
J Bone Miner Res
|
2012
|
0.91
|
|
47
|
Standards for performing DXA in individuals with secondary causes of osteoporosis.
|
J Clin Densitom
|
2006
|
0.91
|
|
48
|
Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk.
|
J Clin Densitom
|
2013
|
0.90
|
|
49
|
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
|
J Clin Densitom
|
2008
|
0.88
|
|
50
|
RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.
|
J Bone Miner Res
|
2014
|
0.85
|
|
51
|
Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis.
|
Calcif Tissue Int
|
2010
|
0.85
|
|
52
|
Renal safety of intravenous bisphosphonates in the treatment of osteoporosis.
|
Expert Opin Drug Saf
|
2007
|
0.85
|
|
53
|
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
|
J Clin Endocrinol Metab
|
2015
|
0.84
|
|
54
|
Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
|
J Clin Densitom
|
2011
|
0.84
|
|
55
|
2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases.
|
J Clin Densitom
|
2013
|
0.83
|
|
56
|
DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults.
|
J Clin Densitom
|
2007
|
0.83
|
|
57
|
Osteoporosis update from the 2012 Santa Fe Bone Symposium.
|
J Clin Densitom
|
2013
|
0.82
|
|
58
|
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
|
Bone
|
2008
|
0.82
|
|
59
|
Use of lowest single lumbar spine vertebra bone mineral density T-score and other T-score approaches for diagnosing osteoporosis and relationships with vertebral fracture status.
|
J Clin Densitom
|
2008
|
0.82
|
|
60
|
Uses and misuses of quantitative ultrasonography in managing osteoporosis.
|
Cleve Clin J Med
|
2006
|
0.82
|
|
61
|
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
|
Osteoporos Int
|
2005
|
0.82
|
|
62
|
Dual-energy X-ray absorptiometry diagnostic discordance between Z-scores and T-scores in young adults.
|
J Clin Densitom
|
2009
|
0.81
|
|
63
|
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
|
J Rheumatol
|
2005
|
0.81
|
|
64
|
What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis?
|
J Clin Densitom
|
2002
|
0.81
|
|
65
|
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
|
N Engl J Med
|
2004
|
0.80
|
|
66
|
Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al.
|
J Clin Densitom
|
2005
|
0.80
|
|
67
|
2008 Santa Fe Bone Symposium: update on osteoporosis.
|
J Clin Densitom
|
2009
|
0.79
|
|
68
|
Bone density testing: science, the media, and patient care.
|
Curr Osteoporos Rep
|
2014
|
0.78
|
|
69
|
Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.
|
J Bone Miner Res
|
2009
|
0.78
|
|
70
|
The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.
|
J Clin Densitom
|
2010
|
0.78
|
|
71
|
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.
|
Endocr Pract
|
2016
|
0.77
|
|
72
|
Diagnostic agreement at the total hip using different DXA systems and the NHANES III database.
|
J Clin Densitom
|
2007
|
0.77
|
|
73
|
Update on osteoporosis from the 2014 Santa Fe Bone symposium.
|
Endocr Res
|
2015
|
0.77
|
|
74
|
Bone-density testing interval and transition to osteoporosis.
|
N Engl J Med
|
2012
|
0.77
|
|
75
|
Editorial: greater risk, greater benefit--true or false?
|
J Clin Endocrinol Metab
|
2003
|
0.77
|
|
76
|
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.
|
Endocr Pract
|
2016
|
0.77
|
|
77
|
All bisphosphonates are (or may not be) the same: potential reasons for clinical differences.
|
J Womens Health (Larchmt)
|
2010
|
0.76
|
|
78
|
FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
|
J Clin Densitom
|
2011
|
0.76
|
|
79
|
Osteoporosis update from the 2010 santa fe bone symposium.
|
J Clin Densitom
|
2011
|
0.76
|
|
80
|
Determinants of bone strength.
|
J Bone Miner Res
|
2003
|
0.75
|
|
81
|
Fragility fractures in chronic kidney disease: A clarification of views (December 2009).
|
Cleve Clin J Med
|
2010
|
0.75
|
|
82
|
Letter to the editor.
|
Bone
|
2004
|
0.75
|
|
83
|
Upper tract surveillance in primary bladder cancer follow-up.
|
BJU Int
|
2004
|
0.75
|
|
84
|
2009 Santa Fe Bone symposium.
|
J Clin Densitom
|
2010
|
0.75
|
|
85
|
Position Development Conference.
|
South Med J
|
2003
|
0.75
|
|
86
|
Skeletal health and bone strength: DXA and beyond growth for the Journal of Clinical Densitometry.
|
J Clin Densitom
|
2008
|
0.75
|
|
87
|
Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007.
|
J Clin Densitom
|
2008
|
0.75
|
|
88
|
Proceedings of the 2011 Santa Fe Bone symposium.
|
J Clin Densitom
|
2012
|
0.75
|
|
89
|
Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women.
|
Menopause
|
2016
|
0.75
|
|
90
|
In Memoriam: Sergio Ragi-Eis, MD, CCD, CDT (April 8, 1962–February 22, 2012).
|
J Clin Densitom
|
2012
|
0.75
|
|
91
|
New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status.
|
J Clin Densitom
|
2006
|
0.75
|